AstraZeneca Clinical Trials AstraZeneca RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

PRostate Olaparib Real World Evidence Study
Condition:   Metastatic Castration-resistant Prostate Cancer Intervention:   Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease control rates of 92% and 93%, respectively Three ongoing pivotal trials... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 10, 2023 Category: Pharmaceuticals Source Type: clinical trials

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Condition:   Asthma Interventions:   Biological: Tezepelumab;   Other: Placebo Sponsors:   AstraZeneca;   Amgen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials